Case number# PHHY2015BR081121, is an initial spontaneous report from a physician via Biogen pharmaceutical 
company (reference no. 2015BI083876) received on 30 Jun 2015. 
This report refers to female patient, born in 1982. Historical drug included Tysabri (natalizumab). Historical and 
current condition were not reported. No concomitant medication was reported. 
The patient received Gilenya (fingolimod) capsule, for an unknown indication, since an unspecified start date, at an 
unknown dose (unknown route). 
On an unknown date, the patient was suspected to have progressive multifocal leukoencephalopathy (PML) 
described as probable immune reconstitution inflammation syndrome (immune reconstitution inflammatory 
syndrome). Action taken with Gilenya was unknown. 
Print Time: 13-JUN-2016 09:36 AM If a field is blank, there is no data for that field Page 132 of 457
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
The outcome of the events, causality and seriousness were not reported by the physician. Seriousness assessment
of immune reconstitution inflammatory syndrome and multifocal leukoencephalopathy was upgraded based on the 
NVS-IME list. 
This case was processed with very limited information received from Biogen and the company. Reporter contact 
details and consent to contact him directly were not provided. The company would do an active follow-up on the 
case after receiving reporter contact details and consent from Biogen.